Non-alcoholic fatty liver from obesity to cirrhosis...Global Therapeutics Market Focuses on Next-Generation Treatment of Various Mechanisms

Sep 22, 2025




Gross Research recently announced the results of an analysis of the global MASH (metabolic steatohepatitis) treatment industry, which is attracting attention related to obesity.

According to the report, the world's obese population reaches about 1 billion, many of which progress to MASH through intrahepatic fat accumulation (MASLD).

MASH is the new international name for non-alcoholic steatohepatitis (NASH). It is a disease that starts with simple fatty liver and can lead to liver cell damage, inflammation, and fibrosis. As symptoms intensify, the mortality rate increases rapidly, and if the timing of treatment intervention is missed, it can lead to liver failure, cirrhosis, and liver cancer.




However, there are only two currently approved treatments: Madrigal Pharmaceuticals' Rezdiffra and Novo Nordisk's Wegovy, pointing out supply shortages and limited efficacy issues.

Madrigal Pharmaceuticals' Resdivra is a THR-β (thyroid hormone receptor-β) agent that is effective in improving fatty liver and lowering liver enzyme levels, but is limited in inhibiting fibrosis progression, and in the case of Novonodisk Semaglutide (Gigobi), it is not a mechanism that directly targets fibrosis with a single GLP-1 sanction.

Therefore, companies such as Boehringer Ingelheim and D&D Pharmatech are effectively approaching MASH treatment through GLP-1 and glucagon receptor (GCGR).




Global pharmaceutical companies are also developing next-generation treatments with various mechanisms such as GLP-1/GIP, GLP-1/Glucagon double and triple agonists, FGF21 family, and amylin-based strategies. In particular, the GLP-1/Glucagon family is attracting attention for reducing liver fat and improving inflammation, and the FGF21 family is attracting attention for improving fibrosis. In addition, RNA-based treatments are being approached from a different axis based on liver-specific gene-based customized treatment. In Korea, D&D Pharmatech, Orix, and Hanmi Pharmaceutical are developing MASH-based treatments.

"MASH is a global health crisis closely related to obesity and metabolic diseases beyond simple liver disease," said Han Yong-hee, CEO of Groth Research. "The pipelines owned by domestic companies have the potential to compete with global big pharma." he evaluated. Just as the success of obesity treatments has exploded the market, MASH treatments will become the next-generation blue ocean in the future, he predicted.






This article was translated by Naver AI translator.